A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L.
Sidarovich V, et al. Among authors: gatto p.
Mol Cancer Ther. 2018 Jul;17(7):1405-1415. doi: 10.1158/1535-7163.MCT-17-0841. Epub 2018 Apr 25.
Mol Cancer Ther. 2018.
PMID: 29695637